GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Policy Acquisition Expense

Ascletis Pharma (HKSE:01672) Policy Acquisition Expense


View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Ascletis Pharma (HKSE:01672) Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.